Article
Jefferies raises AstraZeneca target to 18,000p as analysts flip view on delayed cancer trial
Strong Bullish
100.0
−100 Bearish
0
+100 Bullish
Broker upgrades odds on AVANZAR lung cancer trial after arguing repeated delays signal strong results in treatment arm Jefferies has lifted its price target on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, from 15,000p to 18,000p, reiterating a 'buy'...
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Source
finance.yahoo.com
Published
Mar 6, 2026 · 12:17 pm
Article ID
EAY4BXT
Original URL
Open source
Sentiment Signal
Strong Bullish
100.0
−100Neutral+100
More Like This